HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Juvenile-onset scleroderma

Also Known As:

Juvenile Scleroderma

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Skin and Connective Tissue Diseases
- Skin Diseases: 13127
  - Systemic Scleroderma: 7227
    - Juvenile-onset scleroderma: 2
  - Localized Scleroderma: 954
    - Juvenile-onset scleroderma: 2
- Connective Tissue Diseases: 3269
  - Systemic Scleroderma: 7227
    - Juvenile-onset scleroderma: 2
  - Localized Scleroderma: 954
    - Juvenile-onset scleroderma: 2

Related Diseases

1.	Disease Progression
2.	Vasculitis (Vasculitides)
3.	Rheumatic Diseases (Rheumatism)
4.	Systemic Lupus Erythematosus (Libman-Sacks Disease)
5.	Dermatomyositis (Dermatopolymyositis)

Experts

1.	Tirelli, Francesca: 1 article (01/2020)
2.	Zulian, Francesco: 1 article (01/2020)
3.	Jung, Ju-Yang: 1 article (12/2018)
4.	Kim, Hyoun-Ah: 1 article (12/2018)
5.	Kim, Moon-Young: 1 article (12/2018)
6.	Suh, Chang-Hee: 1 article (12/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Juvenile-onset scleroderma:

1.	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/01/2020 - "The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases."
2.	Methotrexate (Mexate)FDA LinkGeneric 01/01/2020 - "The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases."
3.	tocilizumab (atlizumab)FDA Link 12/14/2018 - "In juvenile-onset scleroderma, for which no therapy that can halt disease progression is available, tocilizumab may stop progression and the associated functional impairment. " 12/14/2018 - "Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. "

Therapies and Procedures

1.	Off-Label Use 12/14/2018 - "Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. "
2.	Therapeutics 12/14/2018 - "In juvenile-onset scleroderma, for which no therapy that can halt disease progression is available, tocilizumab may stop progression and the associated functional impairment. "